Division of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Translational Medicine, Jane and Leonard Korman Lung Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Pharmacology, University of North Carolina, Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
FASEB J. 2018 Feb;32(2):862-874. doi: 10.1096/fj.201700555R. Epub 2018 Jan 4.
GPCRs have diverse signaling capabilities, based on their ability to assume various conformations. Moreover, it is now appreciated that certain ligands can promote distinct receptor conformations and thereby bias signaling toward a specific pathway to differentially affect cell function. The recently deorphanized G protein-coupled receptor OGR1 [ovarian cancer G protein-coupled receptor 1 ( GPR68)] exhibits diverse signaling events when stimulated by reductions in extracellular pH. We recently demonstrated airway smooth muscle cells transduce multiple signaling events, reflecting a diverse capacity to couple to multiple G proteins. Moreover, we recently discovered that the benzodiazepine lorazepam, more commonly recognized as an agonist of the γ-aminobutyric acid A (GABA) receptor, can function as an allosteric modulator of OGR1 and, similarly, can promote multiple signaling events. In this study, we demonstrated that different benzodiazepines exhibit a range of biases for OGR1, with sulazepam selectively activating the canonical Gs of the G protein signaling pathway, in heterologous expression systems, as well as in several primary cell types. These findings highlight the potential power of biased ligand pharmacology for manipulating receptor signaling qualitatively, to preferentially activate pathways that are therapeutically beneficial.-Pera, T., Deshpande, D. A., Ippolito, M., Wang, B., Gavrila, A., Michael, J. V., Nayak, A. P., Tompkins, E., Farrell, E., Kroeze, W. K., Roth, B. L., Panettieri, R. A. Jr Benovic, J. L., An, S. S., Dulin, N. O., Penn, R. B. Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines.
G 蛋白偶联受体 (GPCRs) 具有多种信号转导能力,这基于其能够呈现多种构象。此外,现在人们已经认识到,某些配体可以促进特定的受体构象,并使信号偏向特定的途径,从而以不同的方式影响细胞功能。最近被分离出来的 G 蛋白偶联受体 OGR1 [卵巢癌 G 蛋白偶联受体 1 (GPR68)] 在细胞外 pH 值降低时受到刺激,会表现出多种信号转导事件。我们最近证明,气道平滑肌细胞可以传递多种信号转导事件,这反映了它们与多种 G 蛋白耦联的多样化能力。此外,我们最近发现,苯二氮䓬类药物劳拉西泮,更常见的是作为γ-氨基丁酸 A (GABA) 受体激动剂,可作为 OGR1 的变构调节剂,并同样可以促进多种信号转导事件。在这项研究中,我们证明了不同的苯二氮䓬类药物对 OGR1 具有不同的偏向性,其中舒拉西泮在异源表达系统以及几种原代细胞类型中选择性激活 G 蛋白信号通路的经典 Gs。这些发现强调了偏向性配体药理学在定性上操纵受体信号的潜在力量,以优先激活具有治疗益处的途径。-Pera, T., Deshpande, D. A., Ippolito, M., Wang, B., Gavrila, A., Michael, J. V., Nayak, A. P., Tompkins, E., Farrell, E., Kroeze, W. K., Roth, B. L., Panettieri, R. A. Jr Benovic, J. L., An, S. S., Dulin, N. O., Penn, R. B. 苯二氮䓬类药物对质子感应受体 OGR1 的偏向性信号转导。
Am J Physiol Lung Cell Mol Physiol. 2021-12-1
Am J Physiol Lung Cell Mol Physiol. 2019-2-6
Biochem Biophys Res Commun. 2020-4-10
Genes (Basel). 2024-9-1
Am J Physiol Heart Circ Physiol. 2024-11-1
Am J Respir Cell Mol Biol. 2022-11
Am J Respir Cell Mol Biol. 2022-10
Methods Cell Biol. 2016
Mol Pharmacol. 2015-9
J Biol Chem. 2014-12-26
J Biol Chem. 2014-8-15
Curr Opin Cell Biol. 2013-11-20